Evidence map›Paper›PMID 32637945›Full record

ArticlebioRxiv : the preprint server for biology2020

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities.

Caleb D Swaim, Yi-Chieh Perng, Xu Zhao, Larissa A Canadeo, Houda H Harastani, Tamarand L Darling, Adrianus C M Boon, Deborah J Lenschow, Jon M Huibregtse

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 36 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Caleb D SwaimDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX.
Yi-Chieh PerngDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO.
Xu ZhaoDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX.
Larissa A CanadeoDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX.
Houda H HarastaniDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO.
Tamarand L DarlingDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO.
Adrianus C M BoonDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO.
Deborah J LenschowDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, MO.
Jon M HuibregtseDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX.
Washington University in St. Louis · USThe University of Texas at Austin · US

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Mechanism and Function of ISG15 ConjugationR01AI096090 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI HUIBREGTSE, JON · 2011 to 2025
$5.9M
REGULATION OF INFLUENZA VIRUS INFECTION BY ISG15R01AI080672 · NIAID · WASHINGTON UNIVERSITY · PI LENSCHOW, DEBORAH J · 2009 to 2021
$2.9M
NCATS NIH HHS UL1 TR002345NIAID NIH HHS R01 AI080672NIAID NIH HHS R01 AI096090
6 · The paper itself

Abstract

A recently emerged betacoronavirus, SARS-CoV-2, has led to a global health crisis that calls for the identification of effective therapeutics for COVID-19 disease. Coronavirus papain-like protease (PLpro) is an attractive drug target as it is essential for viral polyprotein cleavage and for deconjugation of ISG15, an antiviral ubiquitin-like protein. We show here that 6-Thioguanine (6-TG) inhibits SARS-CoV-2 PLpro-catalyzed viral polyprotein cleavage and ISG15 deconjugation in cells and inhibits replication of SARS-CoV-2 in Vero-E6 cells and Calu3 cells at submicromolar levels. As a well-characterized FDA-approved orally delivered drug, 6-TG represents a promising therapeutic for COVID-19 and other emerging coronaviruses. ONE SENTENCE SUMMARY: A repurposed drug that targets an essential enzymatic activity of SARS-CoV-2 represents a promising COVID-19 therapeutic.

Identifiers

PMID32637945
PMCPMC7337375
OpenAlexW3040065139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.